SNO Meeting 19 Nov Pediatric (Clinical) Session I CTNI-27 Paxalisib

SNO2020 Virtual Conference November 19-21

Pediatric (Clinical) Session I CTNI-27 - First-in-pediatrics phase I study of GDC-0084 (paxalisib), a CNS-penetrant PI3K/mTOR inhibitor, in newly diagnosed diffuse intrinsic pontine glioma (DIPG) or other diffuse midline glioma (DMG).
Highly aggressive childhood brain tumour
On-Demand Abstract Presenter
Christopher Tinkle - St. Jude Children's Research Hospital
MD, PhD is an Assistant Member in the Department of Radiation Oncology at St. Jude Children’s Research Hospital. He completed undergraduate studies at the University of Texas at Austin, MD/PhD training through the MSTP-supported Tri-institutional MD/PhD program at Weill Cornell Medical College and Rockefeller University, and radiation oncology residency at the University of California, San Francisco. As a clinician-scientist and board-certified radiation oncologist, his focus is on translational studies exploiting DNA repair deficiencies in pediatric high-grade glioma and high-risk bone and soft tissue sarcoma. He shares a joint lab with Dr. Anang Shelat exploring tissue-specific vulnerabilities to combination DNA damaging therapy and emerging inhibitors of the DNA damage response and repair pathways.

https://www.eventscribe.com/2020/SNO/agenda.asp?pfp=LiveSessions

https://www.soc-neuro-onc.org/WEB/WEB/Annual_Conference/Copy_of_Annual_Meeting.aspx

Regards.